Investor Presentation January 2026 Forward Looking Statements This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about the Company's business, financial condition, operating results, plans, object ive s, expectations and intentions, expansion plans, estimates of our total addressable market, our ability to ...

PresentationThanks, everyone, for joining us today. Welcome to the JPMorgan Healthcare Conference. My name is Jaden Rismay, and I'm on the Life Science Tools team here. I'm pleased to be joined by Sotera Health, CEO, Michael Petras. So I'll turn it over here in a second to Michael to get started with the presentation. Afterwards, we'll do the standard Q&A session. And so with that, please take it away, Michael.Michael PetrasChairman & CEO Great. Thanks, Jaden, and good morning, everybody, and I appreciate t ...

CVS Health Corporation (NYSE:CVS) is one of the stocks from different market sectors that Jim Cramer commented on. Cramer made bullish comments on the stock during the episode, as he remarked: “The sixth best sector and the only other sector to finish 2025 up double digits was healthcare, which finished up 12.5%. Coming into last year, there was a lot of worry about what the health and human services department might do to the industry under the leadership of RFK Jr. But when the worst of these fears fail ...

Core Insights - Major U.S. stock market indices closed positively on January 9, 2026, following December jobs data, with unemployment rate decreasing to 4.4% but job additions missing expectations [1] Group 1: Market Trends - Investors are shifting towards dividend-growth stocks due to a preference for quality and visibility amid economic uncertainty, as these stocks signal robust cash flows [2][9] - Stocks with a strong history of year-over-year dividend growth are seen as better investments for capital appreciation compared to simple dividend-paying stocks [3][6] Group 2: Characteristics of Dividend Growth Stocks - Dividend growth stocks belong to mature companies, providing a hedge against market volatility and economic uncertainty while offering downside protection through consistent payout increases [4] - These stocks typically exhibit superior fundamentals, including sustainable business models, profitability, rising cash flows, good liquidity, and strong balance sheets [5] Group 3: Selected Dividend Growth Stocks - Woodward Inc. (WWD): Expected revenue growth of 11.2% for fiscal 2026, long-term earnings growth rate of 15.20%, and annual dividend yield of 0.35% [10][11] - Cardinal Health (CAH): Projected revenue growth of 16.2% for fiscal 2026, long-term earnings growth rate of 13.90%, and annual dividend yield of 1.02% [12] - Fox Corp. (FOX): Anticipated revenue growth of 3.6% for fiscal 2027, long-term earnings growth rate of 10.10%, and annual dividend yield of 0.84% [13] - Kinross Gold (KGC): Expected revenue growth of 11% for fiscal 2026, long-term earnings growth rate of 36.5%, and annual dividend yield of 0.45% [14] - Donaldson (DCI): Projected revenue growth of 3.5% for fiscal 2026, long-term earnings growth rate of 10%, and annual dividend yield of 1.26% [15]

Good morning. The U.S. economy closed out 2025 with a puzzling mix: sluggish job growth alongside accelerating productivity.The U.S. Bureau of Labor Statistics (BLS) reported on Friday that nonfarm payrolls rose by a seasonally adjusted 50,000 in December 2025, missing the 73,000 Dow Jones estimate and slowing from November’s revised gain of 56,000. November payrolls were revised down by 8,000 jobs, while October’s loss deepened to 173,000 from 105,000. For 2025 as a whole, payrolls grew by an average of 49 ...

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and failed to disclose critical information about accounts receivable and liability reserves, leading to significant financial losses for investors during the specified class period [1][3][4]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which allowed the company to report inflated financial figures [3]. - A significant decrease of $43 million in third quarter 2025 revenue was revealed, attributed to revised assessments of accounts receivable collectability after a transition to a new revenue accounting system [4]. - The company cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million – $615 million to $530 million – $555 million, due to ongoing industry-wide cost pressures [4]. Group 2: Professional Liability Concerns - Ardent Health allegedly did not maintain sufficient professional malpractice liability insurance to cover potential claims, which raises concerns about its financial stability [3]. - The lawsuit indicates that the company recorded a $54 million increase in professional liability reserves due to recent settlements and ongoing litigation, reflecting broader industry trends and social inflationary pressures [4]. Group 3: Legal Process and Representation - Investors who purchased Ardent Health securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [5]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having secured over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Sotera Health Company is experiencing solid growth, with revenue expected to exceed $1.16 billion in 2025, marking a year-over-year increase of at least 5.5% [2] Group 1: Company Overview - Sotera Health is a leading global provider of end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry [6] - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [6] - The mission of Sotera Health is to safeguard global health [6] Group 2: Financial Performance - Revenue for 2025 is projected to surpass $1.16 billion, reflecting a growth of at least 5.5% year-over-year or 5.0% on a constant-currency basis [2] - This growth marks over two decades of consecutive year-over-year revenue increases, demonstrating the durability of the company's business model and financial profile [2] - Full-year results and the 2026 outlook will be shared on February 24, 2026 [2] Group 3: Investor Relations - A live webcast of the company's presentation at the J.P. Morgan Healthcare Conference will be available on the Investor Relations section of the company's website [2] - A replay of the presentation will be accessible within 48 hours and archived on the company's website [2]

Group 1 - Ero Copper Corp. (ERO) has seen a Zacks Consensus Estimate for its current year earnings increase by 8.1% over the last 60 days [1] - Nu Holdings Ltd. (NU) has experienced a Zacks Consensus Estimate for its current year earnings rise of 7.1% over the last 60 days [1] Group 2 - Kohl's Corporation (KSS) has reported a Zacks Consensus Estimate for its current year earnings increasing by 104.4% over the last 60 days [2] - Fulgent Genetics, Inc. (FLGT) has seen a significant increase in the Zacks Consensus Estimate for its current year earnings by 775% over the last 60 days [2] - The Beachbody Company, Inc. (BODI) has experienced a Zacks Consensus Estimate for its current year earnings increase of 58.3% over the last 60 days [2]

CVS Health Corporation (NYSE:CVS) is one of the most undervalued blue chip stocks to buy now. Bernstein Raises PT on CVS Health (CVS) to $91, Reiterates ‘Market Perform’ Rating On January 6, 2026, Bernstein increased its price target on CVS Health Corporation (NYSE:CVS) from $87 to $91, while reiterating a ‘Market Perform’ rating. The investment firm expects a broader inflection in the government-managed care organization (MCO) sector beginning in 2026. The firm projects short-term earnings recovery, dri ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 18, 2024, to November 12, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health's Q3 2025 revenue was overstated due to inadequate assessments of accounts receivable collectability following a transition to a new revenue accounting system [3]. - The company's 2025 EBITDA guidance was allegedly overstated and would be reduced by $57.5 million at the midpoint, approximately 9.6%, due to persistent industry-wide cost pressures, including payer denials [3]. - As a result, statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Investor Actions and Legal Representation - Investors who suffered losses in Ardent have until March 9, 2026, to request the Court to appoint them as lead plaintiff, although sharing in any recovery does not require serving as lead plaintiff [4]. - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors nationwide, emphasizing their commitment to restoring investor capital and ensuring corporate accountability [6].